SCHEMBL22749299

SCHEMBL22749299

CCOc1cncc(-c2ccc(NC(=O)C3(c4ccnc(SC)n4)CCOCC3)nc2)n1

nearest known ligand 0.71

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CTPS1 P17812 20/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29142077 0.93 CTPS1 (0.70) CTPS1
SCHEMBL22758541 0.86 CTPS1 (0.74) CTPS1
SCHEMBL21392129 0.85 CTPS1 (0.73) CTPS1
SCHEMBL22736740 0.85 CTPS1 (0.84) CTPS1
SCHEMBL22749250 0.85 CTPS1 (0.84) CTPS1
SCHEMBL29142088 0.83 CTPS1 (0.68) CTPS1
SCHEMBL24849019 0.83 CTPS1 (0.81) CTPS1
SCHEMBL22758548 0.83 CTPS1 (0.81) CTPS1
SCHEMBL22758516 0.83 CTPS1 (0.81) CTPS1
SCHEMBL21381421 0.83 CTPS1 (0.86) CTPS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114008039-B Compounds as human CTPS1 inhibitors for the treatment of proliferative diseases 斯泰普制药股份公司 2024-01-16 — — CN claimed
US-12466810-B2 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases STEP PHARMA S.A.S. (FR) 2025-11-11 — — US disclosed
CN-114008039-B Compounds as human CTPS1 inhibitors for the treatment of proliferative diseases 斯泰普制药股份公司 2024-01-16 — — CN disclosed
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-19 — — US disclosed
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-19 — — US disclosed
US-20230002352-A1 SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-05 — — US disclosed
US-20230002352-A1 SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-05 — — US disclosed
US-20220324837-A1 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases STEP PHARMA S.A.S. (FR) 2022-10-13 — — US disclosed
EP-4041723-A2 SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS Step Pharma S.A.S. (FR) 2022-08-17 — — EP disclosed
EP-4041715-A1 SULFONAMIDE INHIBITORS AS CTPS 1 INHIBITORS Step Pharma S.A.S. (FR) 2022-08-17 — — EP disclosed
EP-3980411-A1 N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Step Pharma S.A.S. (FR) 2022-04-13 — — EP disclosed
CN-114008039-A N- (5- (6-ethoxypyrazin-2-yl) pyridin-2-yl) -4- (2- (methylsulfonylamino) pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases 斯泰普制药股份公司 2022-02-01 — — CN disclosed
WO-2021053402-A2 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-03-25 — — WO disclosed
WO-2021053402-A2 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-03-25 — — WO disclosed
WO-2020245664-A1 N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES STEP PHARMA S.A.S. (FR) 2020-12-10 — — WO disclosed
WO-2020245664-A1 N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES STEP PHARMA S.A.S. (FR) 2020-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS CTPS1, CTPS2, TYMS CTPS1 1/4885
US-20230002352-A1 SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS CTPS1, CTPS2, TYMS CTPS1 1/4885
US-12466810-B2 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases CTPS1, CTPS2, TYMS CTPS1 1/4885
US-20220324837-A1 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases CTPS1, CTPS2, TYMS CTPS1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback